Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says by 2017, 50% of all expenditures for drugs will be in the specialty drug space.
Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says by 2017, 50% of all expenditures for drugs will be in the specialty drug space. “It suffices to say that it’s pharmaceutical manufacturer price increases that are driving or fueling the specialty drug trend with an increase in utilization, and we foresee this growing in the future,” Dr Gleason said. “What’s really interesting is to look at the expenditures of specialty drugs not just on the pharmacy benefit, but the medical benefit.”
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients are for them to live as long and as well as possible.
Read More
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
Read More